Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer? by Linderholm, B et al.
Post-operative adjuvant radiotherapy, delivered to patients with
localized node-negative breast carcinoma (NNBC), has the aim to
eradicate any micrometastases that may still be present in the
breast after surgery (Veronesi et al, 1981; Fisher et al, 1989;
Liljegren et al, 1994). However, there is a significant number of
patients (25–30%) with only locally treated NNBC in which the
tumour relapsed (McGuire, 1988). There are also a subgroup of
patients that displayed an increased morbidity and even hampered
survival after radiotherapy, dependent on suboptimal techniques
used (Cuzick et al, 1994). Nevertheless, there is still a need to
define more properly the subgroup of patients in whom more
extensive therapy could be considered, in order to further optimize
the radiotherapy given. Previously, a diversity of various factors
related to tumours, such as hormone receptors, have shown to be
of value when initiating systemic treatment to patients at risk for
recurrence (Sigurdsson et al, 1990). Tumour vascularization,
measured as microvessel density, has been proposed to be of
independent prognostic value in breast carcinoma patients, with a
worse outcome for patients with a higher vascularity in their
primary tumours (Weidner et al, 1991; Bosari et al, 1992; Horak et
al, 1992; Gasparini et al, 1993,1994; Toi et al, 1993; Fox et al,
1994; Obermair et al, 1995). On the other hand, radiotherapy
requires adequate blood supply, and is suggested as less efficient
in tissues with poor vascularization (Hobson and Denekamp,
1984). As one of the most potent growth factors known, VEGF
induces endothelial cell proliferation and migration, increases
vascular permeability, and co-function with proteolytic enzymes
involved in tumour invasiveness (Ferrara et al, 1989; Lindgren et
al, 1997). A high correlation is suggested between microvessel
density and the expression of vascular endothelial growth factor
(VEGF) (Toi et al, 1996). Recently, we and others proposed VEGF
content to be a predictor of overall survival (OS) in primary breast
carcinoma (Gasparini et al, 1997; Eppenberg et al, 1998;
Linderholm et al, 1998).
This study aimed to determine the predictive value of VEGF for
relapse-free survival (RFS) and overall survival (OS) in 302
consecutive node-negative patients treated with locoregional
radiotherapy following conservative surgery. As far as we have
found, no other controlled evaluation has been undertaken to
specifically define the prognostic value of vascularization or
VEGF with regard to radiotherapy and survival.
MATERIALS AND METHODS
Patient data
Clinical information and tumour samples were collected from 302
consecutive unselected women with invasive node-negative breast
carcinoma (NNBC), diagnosed and primarily treated for localized
tumour between 1990 and 1995 in the health care region of
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Summary The aim of this study was to determine the association of vascular endothelial growth factor (VEGF) content in 302 consecutive node-
negative breast cancer (NNBC) patients treated with only locoregional radiotherapy to relapse free- (RFS) and overall survival (OS). VEGF
content in tumour cytosols was measured by an enzymatic immunoassay for the major isoform VEGF165. The median age was 56 years, the
median follow-up time 56 months. A wide range (0.01–144.79 pg mg–1 DNA) of VEGF content was found (median 1.92). Significant associations
were found between VEGF and oestrogen receptor (ER) content, progesterone receptor (PR) and tumour size (P = 0.005). Univariate analysis
displayed significant reduced RFS and OS for patients with higher VEGF content (P = 0.0113 and P = 0.0075 respectively). A total of 43
recurrences have been found (ten local relapses within the breast, five in the axillary or supraclavicular lymph nodes and 28 distant metastasis).
There was no significant correlation between the localization of the relapse and the VEGF content. Multivariate analysis suggested VEGF as the
only predictor of OS (relative risk (RR) = 3.6, 95% confidence interval (CI) = 0.97–13.37), and in patients with T1 tumours (n = 236) the
multivariate analysis clearly displayed VEGF as the only independent predictor of both RFS and OS (RR = 5.1, CI = 1.07–24.59). In the sub-
group with ER-positive tumours (n = 229), multivariate analysis showed VEGF as the only significant predictor of RFS and OS (RR = 10.44, CI
= 1.26–86.38). The results suggest VEGF165 as a predictor of RFS and OS in NNBC patients treated with locoregional radiotherapy, comprising
especially patients with favourable prognosis of T1 tumours, or ER-positive tumours. The high VEGF expression might define a radioresistant
phenotype, or indicate an early distant spread which might require adjuvant systemic treatment. © 1999 Cancer Research Campaign
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Correspondence to: R Henrikssonnorthern Sweden. The median age was 56 years (range 29–74),
and the median follow-up time for survivors was 56 months (range
22–91 months). The patients included had histologically verified
invasive unilateral breast carcinoma without axillary lymph node
involvement, or detectable distant metastasis (T1–2, N0, M0). A
total of 236 patients had T1 tumours. Tumour classification and
staging was in accordance with the International Union Against
Cancer tumour-node-metastasis (UICC-TNM) classification.
Primary treatment was given according to the guidelines of the
North Swedish Breast Cancer Group. All patients were treated
with segmental resection with axillary dissection. In the group
with T2 tumours (21–50 mm) (n = 66) no upper limit concerning
the maximum size of the tumour was set for treatment with sector
resection. Surgery was followed by radiotherapy delivered daily at
2-Gy fractions, 5 days per week to a total dose of 56 Gy.
Radiotherapy was started within 4–6 weeks after surgery. The
axilla were not included in the target volume. No patients received
any adjuvant systemic treatment. The end points determined were
local relapses, distant metastasis and survival. Patients with
concomitant local failure and distant metastasis as first event were
classified in the metastasis group. The number of patients for
whom data were available varied among different prognostic
factors studied, but in all cases tumour size, oestrogen receptor
(ER), progesterone receptor (PR) and tumour cytosol VEGF
protein were measured (Table 1). The analyses of tumour tissue
were performed prior to radiotherapy and blindly to the clinical
data.
Tumour tissue preparation, VEGF and receptor analysis
During primary surgery, and after pathological examination, repre-
sentative tumour tissue was cut out and frozen in liquid nitrogen
until analysis. Frozen tumour tissue was homogenized in a
microdish membrator (Braun, Melsungen, Germany) and sus-
pended in cold standard receptor buffer (10 mM Tris pH 7.4,
1.5 mM EDTA, 10 mM sodium molybdate, 1.0 mM monothioglyc-
erol). Supernatants were collected after 10 min refrigerated
centrifugation at 20 000 g and used for analyses of steroid receptor
and VEGF protein contents. The pelleted fractions were analysed
for DNA content by the method of Burton, in order to evaluate cell
concentrations in samples. A high correlation is observed between
DNA content and protein content (r > 0.90). The reason to choose
DNA content for evaluating tumour cellularity in patients’
samples for routine receptor analyses is to avoid measurements of
extracellular proteins. DNA quantification has therefore been
considered more specific than total protein concentration (Norgren
et al, 1986).
VEGF was analysed using a quantitative immunoassay kit for
human VEGF165 (Quantikine, human VEGF, R & D Systems,
Minneapolis, MN, USA). VEGF165 is the most commonly found
isoform of VEGF in both normal and transformed cells (Scott et al,
1998).
ER and PR content was determined by an enzyme immunoassay
(Abbott Laboratories, Diagnostic Division, Abbott Park, IL,
USA). Receptor concentration was expressed as fmol receptor per
mg DNA, and tumours with a value lower than 0.1 fmol ER or
PR mg–1 DNA were considered as receptor-negative, those with a
value equal to or higher than 0.1 fmol ER or PR mg–1 DNA as
receptor-positive.
Statistical methods
Association between VEGF165 content and earlier established
prognostic or predictive factors were tested by the Pearson c2 test.
Survival was estimated using the Kaplan–Meier method, and
comparison between study groups was performed with the log-
rank test. The cut-off value used was the median level of VEGF in
this group of patients. To evaluate the simultaneous effect on
different factors on survival, the Cox proportional hazard model
was used. The survival time was measured from date of diagnosis
to the date of the first relapse or death. In all tests the significance
level was set to 0.05, and all were two-sided tests.
RESULTS
Distribution of VEGF165
The median value was 1.92 pg mg–1 DNA; however, a wide
quantitative range of cytosolic VEGF165 protein was found (range
0.01–144.79). Among the other prognostic variables, VEGF
(≤ 1.92 vs > 1.92 pg mg–1 DNA) was associated with ER content
(ER-positive vs -negative, P < 0.002), PR content (PR-positive vs
-negative, P = 0.006) and tumour size (≤ 2 cm vs 2.1–5.0 cm,
P = 0.005). A borderline value was seen between VEGF and
higher histological grade (grades I + II vs III, P = 0.053). No
association was found between VEGF and histopathological type
(ductal vs lobular and others, P = 0.192), or between VEGF and
age (≤ 56 years vs > 56 years, P = 0.730).
Association between the site of first relapse and VEGF
content
A total of 43 relapses were found. There were ten in-breast fail-
ures, five metastasis in the axillary or supraclavicular lymph nodes
and 28 distant metastasis as first events. One patient had both local
failure and visceral metastasis as first event and classified in the
distant metastasis group. There was no statistically significant
correlation between the localization of the first relapse and the
VEGF content (P = 0.773). In the group with local recurrence
within the breast, 70% (n = 7 of 10) had a VEGF content above the
median value, compared to 80% (n = 4 of 5) in the group with
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Table 1 Clinicopathologic characteristics of the patients
Variables No. of patients
Patients enrolled 302
Histological type
Ductal invasive 258
Lobular invasive 14
Others 30
Tumour size
T1 236
T2 66
Histopathological grading
I2 9
II 113
III 95
Not analysed 65
Oestrogen receptor (ER)
pos (³ 0.1 fmol mg–1 DNA) 229
neg (< 0.1 fmol mg–1 DNA) 73
VEGF levels (pg mg–1 DNA)
All patients (median, range) 302 1.92 (0.01–144.79)lymph node metastasis and 64% (n = 18 of 28) in patients with
distant metastasis.
Univariate analysis
A statistically significant difference in RFS and OS (≤ 1.92 vs
> 1.92 pg mg–1 DNA), was found, with reduced survival times for
patients with a higher level of cytosolic VEGF (P = 0.0113, Figure
1A; and P = 0.0075, Figure 1B respectively). In addition to VEGF,
histological grade (I + II vs III) (P = 0.0158) and tumour size
(T1 vs T2) (P = 0.0020) were statistically significant for RFS,
while ER status (positive vs negative) (P = 0.9579), histological
type (ductal vs lobular and others) (P = 0.6205) and age (≤ 56
years vs > 56 years) (P = 0.1580) were not. Moreover, histological
grade and ER status were statistically significant for OS in
univariate analyses (P = 0.0496 and P = 0.0286 respectively).
Morphological features (P = 0.7300), tumour size (P = 0.6869)
and age (P = 0.7738) were not significant for OS in this material.
Univariate analysis in the subgroup with T1 tumours (n = 236)
showed statistically significant reductions in RFS (P = 0.0007) and
OS (P = 0.0065) for patients with VEGF content above the median
value 1.92 pg mg–1 DNA. Univariate analysis in the sub-group with
ER-positive tumours (n = 229) showed VEGF as a predictive
factor for RFS (P = 0.0012) and OS (P = 0.0006), with reduced
survival times for patients with VEGF content above the median
value (1.92 pg mg–1 DNA).
Multivariate analysis
Analysis of the joint effect of combining VEGF determination
with the other prognostic factors, and age in order to avoid an
effect of age-related mortality, proposed VEGF as the only valu-
able predictor of overall survival (P = 0.0554; confidence interval
(CI) = 0.97–13.4). Patients with higher VEGF values in tumours
(> 1.92 pg mg–1 DNA) had a 3.62 times increased risk of death than
those with lower VEGF values. The other included factors, tumour
size, ER content, histological grade and age failed to retain as
independent predictors for OS in multivariate analysis (Table 2).
For RFS, histological grade was the only independent predictive
factor (P = 0.0289; relative risk (RR) = 2.29, CI = 1.09–4.81), while
VEGF failed as an independent predictor of RFS (P = 0.1406),
though still with an increased risk for recurrence of 1.77. Tumour
size, ER status and age were not significant predictors of RFS.
The results from multivariate analysis in the group with only T1
tumours (n = 236), showed VEGF as the only independent
predictor of RFS (P = 0.0038, RR = 5.18, CI = 1.70–17.78) and OS
(P = 0.0313, RR = 5.62, CI = 1.17–27.27), while the other factors
included failed (Table 3). The results from multivariate analysis in
the sub-group with ER-positive tumours (n = 229), showed histo-
logical grade (P = 0.0192, RR = 2.71, CI = 1.18–6.24) and VEGF
(P < 0.0402, RR = 248, CI = 1.04–5.93) as independent predictors
VEGF and radiotherapy in node-negative breast carcinoma 729
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Figure 1 The probability of (A) relapse-free survival (P = 0.0113) and
(B) overall survival (P = 0.0075) for 302 node-negative patients primary
treated with conservative surgery followed by radiotherapy according to
vascular endothelial growth factor (VEGF). The cut-off value used is the
median level in this group (1.92 pg mg–1 DNA)
Table 2 Multivariate Cox regression analysis on relapse free (RFS) and overall survival (OS) in all 302 node-negative breast cancer patients treated with
segmental resection + radiotherapy
RFS OS
Variable RR 95% CI P RR 95% CI P
VEGF
≤ 1.92 vs >1.92 pg mg–1 DNA 1.77 0.83–3.79 0.1406 3.62 0.97–13.5 0.0554
Estrogen receptor
ER– vs ER+ 1.38 0.59–3.21 0.4533 2.06 0.68–6.17 0.1988
Tumour size
T1 vs T2 1.99 0.95–4.19 0.0682 1.08 0.27–2.94 0.8692
Histopathological grade
I+II vs III 2.29 1.09–4.81 0.0289 1.95 0.62–6.13 0.2530
Age, years
≤ 56 vs > 56 1.03 0.50–2.12 0.9335 1.03 0.37–2.92 0.9437of RFS. For OS, VEGF was the only significant predictor (P =
0.0296, RR = 10.44, CI = 1.26–86.39), while the other factors
included failed (Table 4).
DISCUSSION
The hypothesis to be tested in this study was specifically to
explore the possibility that VEGF, as an indicator of the degree
of vascular activity, could predict the efficacy of locoregional
radiotherapy in breast carcinoma after conservative surgery.
Radiotherapy is known to reduce local recurrence, and recently
has also been proposed to enhance survival (Overgaard et al,
1997). The present results from 302 consecutively sampled
tumours indicate that VEGF165 could be of value as a predictor of
both RFS and OS in women subjected to locoregional therapy for
breast carcinoma. The correlation was especially seen in patients
in general considered to have a good prognosis, i.e. T1 tumours or
ER-positive tumours, with an increased risk of recurrence and
death of 5.18 and 2.48 (RFS) and 5.62 and 10.44 (OS) respec-
tively. In these sub-groups we could thus identify patients with a
high risk of recurrence or death, and consequently surgery
followed by radiotherapy is not sufficient.
However, it has to be emphasized that with regard to RFS,
VEGF was found as a non-significant factor, but with an increased
risk of recurrence of 1.77. Still, multivariate analysis showed
VEGF as an independent predictor of overall survival with a 3.6
times increased risk of death for patients with higher VEGF165
content. Having in mind that this study had relatively short follow-
up (56 months) and few events, 43 recurrences and 16 deaths,
prolonged follow-up may change the results. It has to be stressed
that other factors such as local or systemic therapy delivered after
relapses could influence the survival times. It has been shown that
tumours with a high angiogenic activity, measured by counting
vessel density, seem to be less sensitive to endocrine treatment or
chemotherapy than tumours with lower vessel density (Gasparini
et al, 1995, 1996). Although women with local relapses have an
increased risk of distant metastases, the 5-year survival rate has
been reported as close to 70%. In a large study consisting of more
than 2000 node-negative patients treated with quadrantectomy
followed by radiotherapy, the only factor associated with an
increased risk of local relapse, not of distant metastasis, was an
extensive intraductal component (Veronesi et al, 1995). Moreover,
in this study low histological grade was the strongest factor for
RFS, but not of significance for OS, which is in accordance with
our results.
Due to different splicing, VEGF exists in at least four different
isoforms with 121, 189 and 206 amino acids (VEGF121, VEGF165,
VEGF189 and VEGF206 respectively), which have different affini-
ties to heparin. VEGF165 is the predominant isoform secreted by a
variety of both normal and transformed cells. A significant propor-
tion remains bound to the cell surface and the extracellular matrix.
For those reasons, we chose to measure VEGF165. Moreover,
VEGF165 has been reported as the major protein isoform, despite
the fact that mRNA from also VEGF121 and VEGF189 are present in
human breast carcinoma (Scott et al, 1998).
The effects of irradiation are known to be, at least partially,
dependent on oxygen tension and thus the vascular supply to
tumours (Hobson and Denekamp, 1984; Folkman, 1990). Higher
levels of VEGF have been reported in ‘normal’ tumour-adjacent
tissue than in breast tissue in the contralateral breast and this might
imply a higher vascularization and subsequently increased
radiosensitivity (Schlaeppi et al, 1996). On the other hand,
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Table 3 Multivariate Cox regression analysis on relapse-free (RFS) and overall survival (OS) in 236 patients with T1 node-negative breast cancer tumours
RFS OS
Variable RR 95% CI P RR 95% CI P
VEGF
≤ 1.92 vs >1.92 pg mg–1 DNA 5.18 1.70–17.78 0.0038 5.62 1.17–27.27 0.0313
Estrogen receptor
ER– vs ER+ 1.44 0.46–4.53 0.5325 1.71 0.45–6.40 0.4254
Histopathological grade
I+II vs III 1.89 0.74–4.83 0.1854 1.57 0.41–5.91 0.5075
Age, years
≤ 56 vs > 56 1.97 0.79–4.89 0.1434 2.37 0.68–8.25 0.1727
Table 4 Multivariate Cox regression analysis on relapse-free survival (RFS) overall survival (OS) in 229 patients with oestrogen receptor-positive
node-negative breast cancer tumours
RFS OS
Variable RR 95% CI P RR 95% CI P
VEGF
≤ 1.92 vs >1.92 pg/mg DNA 2.48 1.04–5.93 0.0402 10.44 1.26–86.4 0.0296
Tumour size
T1 vs T2 2.02 0.85–4.80 0.1128 0.56 0.68–4.60 0.5902
Histopathological grade
I+II vs III 2.71 1.18–6.24 0.0192 2.67 0.63–11.26 0.1808
Age, years
≤ 56 vs > 56 1.14 0.50–2.62 0.7435 1.30 0.32–5.26 0.7159hypoxia has shown to up-regulate VEGF, both at mRNA and
protein level, in tumour cell lines and around the necrotic foci of
tumours (Shweiki et al, 1992; Scott et al, 1998). It has also earlier
been reported a high correlation between microvessel density and
the expression of VEGF (Toi et al, 1996). Nevertheless, paradoxi-
cally or not, the present observation in contrary showed that a
higher content of VEGF is associated with a reduced RFS and OS
following radiotherapy. Patients with a higher VEGF expression
seem to be more likely to have a local recurrence or to develop
distant metastasis. No significant correlation was found between
the increased VEGF content and the site of the first metastasis.
However, the number of events were too small for definite conclu-
sions. The results find support in previous studies that showed
microvessel density and VEGF content to be a predictor of
survival in breast carcinoma patients, regardless of primary and
adjuvant systemic treatment (Bosari et al, 1992; Gasparini et al,
1993; Toi et al, 1993; Fox et al, 1994; Obermair et al, 1995;
Linderholm et al, 1998).
We thus conclude that VEGF content in the primary tumour
might be a predictor of relapse-free and, most important, overall
survival in node-negative breast cancer treated by locoregional
radiotherapy. The high VEGF content associated to a worse
outcome might be a result of a radioresistant phenotype, or an
early disseminated disease which requires adjuvant systemic
therapy. These issues deserve further studies.
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